Viatris announces exclusive licensing agreement with lexicon pharmaceuticals for sotagliflozin in all markets outside of the u.s. and europe

Continues to expand viatris' innovative portfolio in cardiovascular diseases leverages viatris' unique global infrastructure and expertise includes opportunities to leverage the potential of sotagliflozin to additional indications pittsburgh , oct. 16, 2024 /prnewswire/ -- viatris inc. (nasdaq: vtrs), a global healthcare company, today announced it has entered into an exclusive licensing agreement with lexicon pharmaceuticals, inc. (nasdaq: lxrx) for sotagliflozin in all markets outside of the united states and europe. sotagliflozin was approved by the u.s. food and drug administration in may 2023 to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.
VTRS Ratings Summary
VTRS Quant Ranking